Lupin launches drug to treat OCD
06 February 2019 | News
Lupin’s Clomipramine Hydrochloride Capsules is the generic equivalent of SPECGX LLC’s Anafranil Capsules.
Image credit- drugfree.org
Pharma major Lupin recently announced the launch of Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg is the generic equivalent of SPECGX LLC’s Anafranil Capsules, 25 mg, 50 mg, and 75 mg. It is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).
Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg had annual sales of $96.2 million in the US (IQVIA MAT December 2018).
